(MedPage Today) — DENVER — Biological agents targeting interleukin-4 receptor alpha (IL-4Rα) in atopic dermatitis (AD) achieved rapid and substantial improvement in up to three-fourths of patients, according to randomized trials from China…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
